Our analysis of 18 prospective phase II clinical trials of various treatments for NSCLC patients with HER2 alterations revealed promising treatment outcomes with trastuzumab deruxtecan, trastuzumab emtansine, pyrotinib, pyrotinib + apatinib and trastuzumab + pertuzumab + docetaxel. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.